What is selumetinib?

Selumetinibis anantineoplastic agent indicated for the treatment of neurofibromatosis type 1 in patients aged ≥2 years of age1 an>(NF1)in pediatric patients with symptomatic, inoperable plexiform neurofibromas(has been designated as an orphan drug by the FDA).

Selumetinib is mainly composed of cytochromeP-450 (CYP) 3A4Metabolized, followed by CYPisoenzymes2C19, 1A2, 2C9, 2E1 and 3A5 metabolism. Selumetinib is also glucuronidated by UGT1A1 and UGT1A3. Selumetinibis metabolized to the active metabolite N-desmethylSelumetinib is produced by CYP2C19 and CYP1A2 is mediated, and there are also CYP2C9 and CYP2A6. N-Desmethyl selumetinib has the same metabolic pathway as selumetinib . In vitro, does not inhibit CYPisoenzymes1A2, 2A6, 2B6, 2C8, 2A6 span>2C9, 2C19, 2D6, 3A4 or 2E1. Does not induceCYPisoenzyme3A4, 1A2 or 2B6. Does not inhibit breast cancer resistance protein(BCRP), P-glycoprotein(P-gp), OATP1B1, OATP1B3< transporters. Substrate of BCRP and P-glycoprotein transporters.

Patients should inform their doctor if they are taking supplements containing vitaminE, vitaminK antagonists, or antiplatelet agents. Inform pregnant women and women of reproductive potential of the potential risks to the fetus. Advise women of childbearing potential to inform their healthcare provider of known or suspected pregnancy. Advise females of reproductive potential to use effective contraception during treatment with selumetinib sulfate and for1weeks after the last dose. Advise men with female partners of reproductive potential to use effective contraception during treatment with selumetinib and for at least 1 week after the last dose. Advise women not to breastfeed during treatment with selumetinib and for 1 week after the last dose. There is an original research version of selumetinib overseas, with a retail price of 10 mg 60 tablets 50,000around. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.